Update on Dendritic Cell-Induced Immunological and Clinical Tolerance.

Détails

Ressource 1Télécharger: 29250057_BIB_94A03CF5154C.pdf (762.26 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_94A03CF5154C
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Update on Dendritic Cell-Induced Immunological and Clinical Tolerance.
Périodique
Frontiers in immunology
Auteur(s)
Obregon C., Kumar R., Pascual M.A., Vassalli G., Golshayan D.
ISSN
1664-3224 (Print)
ISSN-L
1664-3224
Statut éditorial
Publié
Date de publication
2017
Peer-reviewed
Oui
Volume
8
Pages
1514
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Résumé
Dendritic cells (DCs) as highly efficient antigen-presenting cells are at the interface of innate and adaptive immunity. As such, they are key mediators of immunity and antigen-specific immune tolerance. Due to their functional specialization, research efforts have focused on the characterization of DCs subsets involved in the initiation of immunogenic responses and in the maintenance of tissue homeostasis. Tolerogenic DCs (tolDCs)-based therapies have been designed as promising strategies to prevent and control autoimmune diseases as well as allograft rejection after solid organ transplantation (SOT). Despite successful experimental studies and ongoing phase I/II clinical trials using autologous tolDCs in patients with type 1 diabetes, rheumatoid arthritis, multiple sclerosis, and in SOT recipients, additional basic research will be required to determine the optimal DC subset(s) and conditioning regimens for tolDCs-based treatments in vivo. In this review, we discuss the characteristics of human DCs and recent advances in their classification, as well as the role of DCs in immune regulation and their susceptibility to in vitro or in vivo manipulation for the development of tolerogenic therapies, with a focus on the potential of tolDCs for the treatment of autoimmune diseases and the prevention of allograft rejection after SOT.

Mots-clé
autoimmune diseases, immunotherapy, solid organ transplantation, tolerance, tolerogenic dendritic cells
Pubmed
Web of science
Open Access
Oui
Création de la notice
10/01/2018 9:50
Dernière modification de la notice
20/08/2019 14:57
Données d'usage